CC
ROIV icon

Chicago Capital’s Roivant Sciences ROIV Stock Holding History

Chicago Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-938,113
Closed -$3.02M – 238
2022
Q3 		$3.02M Hold
938,113
– – 0.17% 66
2022
Q2 		$3.82M Buy
+938,113
New +$3.72M 0.21% 65

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Chicago Capital's ROIV Position: Q4 2022 in Review

Chicago Capital sold out of Roivant Sciences (ROIV) in Q4 2022, closing a stake of 938,113 shares — an estimated $3.02M sold.

Chicago Capital first reported a position in ROIV in Q2 2022 and held it in 2 quarters. The position peaked at $3.82M in Q2 2022. 110 funds tracked by Wall St. Rank hold ROIV as of Q4 2022.

  • Chicago Capital reported no remaining Roivant Sciences position as of Q4 2022 after selling out during the quarter.
  • Chicago Capital sold 938,113 Roivant Sciences shares in Q4 2022, an estimated $3.02M.
  • Chicago Capital first reported a position in Roivant Sciences in Q2 2022 and held it in 2 quarters.
  • Chicago Capital's Roivant Sciences position peaked at $3.82M in Q2 2022.
  • 110 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2022.

Based on Chicago Capital's 13F filing for Q4 2022, filed 20 Jan 2023.